Found 195 clinical trials
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
provides poor therapeutic effect, leading to tumor progression or intolerance. Before immunotherapy, the PD-L1 expression was confirmed negative in the graft liver by immunohistochemistry, and patients
- 0 views
- 15 May, 2022
- 1 location
Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)
180 days. Risk assessment will include seizure, stroke, infection, tumor progression, and death.
- 20 views
- 14 Jul, 2022
- 1 location
An Open-Label Multi-Center Phase II Study of Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
antibody such as tocilizumab may inhibit cancer progression. Giving atezolizumab in combination with etrumadenant or tocilizumab may work better in treating prostate cancer.
- 9 views
- 27 Oct, 2022
- 1 location
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
, 2) allow for optimal chemotherapeutic dosing to achieve the greatest benefits and the least systemic side effects and 3) distinguish subsequent tumor progression from long-term MLA treatment effects
- 35 views
- 09 Jul, 2022
- 1 location
Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases
, disease-free survival and quality of life for 5 years and compared to a "control group" of participants who drop out of study prior to transplantation due to reasons other than cancer progression.
- 206 views
- 20 Apr, 2022
- 1 location
Group Exercise Training for Fall Prevention and Functional Improvements During and After Treatment for Prostate Cancer
exposure and slow down cancer progression. While beneficial for cancer survival, significant treatment-induced side effects from ADT may lead to serious health consequences including falls, frailty, and
- 3 views
- 12 Oct, 2022
- 1 location
A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)
ipilimumab. Subjects may continue receiving study drugs until cancer progression, severe toxicity, withdrawal of consent, 3 years from the initial dose of study drugs or study termination, whichever occurs
- 8 views
- 17 Jun, 2022
- 1 location
A Study of RGX-202-01 as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202
- 310 views
- 04 Oct, 2022
- 5 locations
Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma
prevent tumor progression in patients with recurrent, residual GBM.
- 283 views
- 28 Oct, 2022
- 1 location
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
explore the effects of each drug on the immune system. Undergo scans every 6 weeks to test the effect of treatment on cancer progression. Undergo other study procedures to evaluate drug
- 0 views
- 11 Apr, 2023
- 3 locations